In an expanded, 3-year clinical trial of 86 patients with colorectal and 11 other cancers with so-called ‘mismatch repair’ genetic defects, scientists have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda), as reported in Science.

See the source article by following the link below:
In an expanded, 3-year clinical trial of 86 patients with colorectal and 11 other cancers with so-called ‘mismatch repair’ genetic defects, scientists have found that half of the patients respond to an immunotherapy drug called pembrolizumab (Keytruda), as reported in Science.